Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies.

ABSTRACT: Prognosis in therapy-related acute myeloid leukemia (T-AML) remains poor, but understanding outcomes with venetoclax (VEN)-based therapy is relevant. We retrospectively analyzed 317 adult patients with newly diagnosed T-AML focusing on lower intensity therapy (LIT) VEN-containing regimens. Patients with an antecedent myeloid disorder before AML diagnosis were excluded. The median age was 69 years (range 21-92); 50% evaluated patients had a complex karyotype, and 40% evaluated patients had a TP53 mutation. Composite complete response rates were higher with LIT + VEN compared to LIT (58% vs. 40%, P = 0.003) but were similar in intensive chemotherapy (IC) + VEN versus IC alone (68% vs. 61%, P = 0.59). Rates of allogeneic hematopoietic stem cell transplantation (HSCT) were higher in VEN

SUBMITTER: Senapati J 

PROVIDER: S-EPMC12895360 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature